MMDP in Burkina Faso
Estimates show that 35,000 people in Burkina Faso suffer from trachomatous trichiasis. Meanwhile, disfigurement and disability due to lymphatic filariasis have been documented in all of the country’s health districts. These are the lasting effects of long-ago infections.
This picture of lingering suffering stands in contrast to Burkina Faso’s dramatic successes in breaking transmission of trachoma and lymphatic filariasis infection through mass drug administration. As one of the original countries chosen by USAID a decade ago to receive support for mass drug administration in all endemic districts, Burkina Faso has today reached a point where treatment can stop in 91 percent of districts that previously received drugs for trachoma, and 56 percent of districts that previously required drugs for lymphatic filariasis. Nevertheless, without significant, sustained investment to address the disability side of the equation, Burkina Faso will not fully be able to eliminate trachoma and lymphatic filariasis as public health problems.
The MMDP Project is giving Burkina Faso the boost it needs. Complementing the longstanding mass drug administration program, the MMDP Project is stepping in with a large-scale investment and a sense of urgency to improve the health and lives of those harmed by past infections. In an effort led by the Ministry of Health, the MMDP Project helps strengthen local capacity to provide high-quality services for people with trichiasis, hydrocele and lymphedema.